MDCO-2010 is an antifibrinolytic, i.e. it inhibits the inhibition of clot formation, which thereby reduces blood loss. Paradoxically, MDCO-2010 is also an anticoagulant, but its anticoagulant activity is apparently weak enough to not cause a problem.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”